3 ESG conference call Strategic Aspirations 2025 with to sustainability • Being respected for adding value to society • Progress towards zero environmental impact • Ensure distinct core capabilities and evolve culture • Strengthen Diabetes leadership - aim at global value market share of more than 1/3 • Strengthen Obesity leadership and double current sales1 • Secure a sustained growth outlook for Biopharm 1 Based on reported sales in 2019 2 From 2015 to 2022. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic
Download PDF file